Emulate, Inc. and AstraZeneca form strategic agreement to work side-by-side on Organs-on-Chips technology to improve prediction of human safety and efficacy of drug candidates

From Startup Emulate Bio

Link to Full Article: https://emulatebio.com/press/emulate-astrazeneca-partner/

An initial focus will be to use Emulate’s Liver-Chip for safety testing of drug candidates across the AstraZeneca pipeline with the goal of submitting Organ-Chip data within the regulatory framework for new drugs.  The terms of the agreement also allow for Emulate’s technology to be adopted across AstraZeneca’s therapeutic areas and will enable the two companies to develop functionality of three other Emulate Organ-Chips — the Lung Tumor-Chip, Lung-Chip, and Glomerulus Kidney-Chip.  By delivering new insights into human disease mechanisms, scientists will be more equipped to predict the clinical relevance of candidate drug safety and efficacy.
About the “Human Emulation System” Powered by Organs-On-Chips Technology
Based on Organs-on-Chips technology, Emulate has created a new living Human Emulation System™ that provides a real-time window into the inner workings of human biology and disease – offering researchers a new technology designed to predict human response with greater precision and detail than today’s cell culture or animal-based experimental testing. Each of Emulate’s proprietary Organ-Chips — including the lung, liver, brain, intestine and kidney — contains tiny hollow channels lined with tens of thousands of living human cells and tissues, and are approximately the size of an AA battery. An Organ-Chip is a living, micro-engineered environment that recreates the natural physiology and mechanical forces that cells experience within the human body.
About Emulate, Inc.
Emulate Inc. is a privately held company that creates living products for understanding how diseases, medicines, chemicals, and foods affect human health. Our Human Emulation System™ sets a new standard for recreating true-to-life human biology, and is being used to advance product innovation, design, and safety across a range of applications including drug development, agriculture, cosmetics, food, and chemical-based consumer products. Emulate continues to develop a wide range of Organ-Chips and disease models through collaborations with industry partners and internal R&D programs. Emulate is also working with clinical partners to produce Organ-Chips personalized with an individual patient’s stem cells, for applications in precision medicine and personalized health. Our founding team pioneered the Organs-on-Chips technology at the Wyss Institute for Biologically Inspired Engineering at Harvard University. Emulate holds the worldwide exclusive license from Harvard University to a robust and broad intellectual property portfolio for the Organs-on-Chips technology and related systems.
Media Contact:For Emulate:Kathryn MorrisTel:  914-204-6412kathryn@theyatesnetwork.com
Image 1 & 2 caption:Emulate’s Organ-Chip technology
 

Please visit their site for more information: Emulate Bio.com

All,Biotechnology,Healthcare News,Startup News
2018-07-05 19:27:23